Form 4: Neurocrine Biosciences Executive Eric Benevich Reports Stock Transactions
SEC Form 4
Chief Commercial Officer Eric Benevich of Neurocrine Biosciences reports acquisition and disposal of common stock and derivative securities, including stock options and restricted stock units, under a pre-arranged trading plan.
Summary
- Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences, filed a Form 4 detailing changes in beneficial ownership.
- The report includes transactions from February 12, 2025, and February 13, 2025.
- Benevich acquired and disposed of Neurocrine Biosciences common stock.
- He also acquired stock options and restricted stock units (RSUs).
- Some transactions were executed under Rule 10b5-1 trading plans adopted in March 2023 and June 2024.
- On February 13, 2025, he sold 1,098 shares at a weighted average price of $116.7421 and 1,056 shares at a weighted average price of $116.7091.
- He acquired 42,805 stock options exercisable at $117.18 on February 12, 2025.
- He also acquired 8,022 restricted stock units vesting annually beginning February 12, 2026.
Sentiment
Score: 6
Explanation: The sentiment is neutral. While there are stock sales, they are under a pre-arranged plan. The acquisition of options and RSUs is a positive sign, but overall, the information is standard for insider trading disclosures.
Positives
- The reporting person's transactions are conducted under pre-arranged 10b5-1 trading plans, suggesting a structured and compliant approach to stock sales.
- The reporting person acquired 42,805 stock options, indicating a continued investment in the company's future.
Negatives
- The reporting person disposed of shares of common stock, which could be interpreted negatively by some investors, although it is part of a pre-arranged plan.
Risks
- Continued stock sales by insiders, even under 10b5-1 plans, could exert downward pressure on the stock price.
- Changes in the executive's holdings could reflect their sentiment about the company's prospects, although this is not explicitly stated.
Future Outlook
The report details future vesting dates for restricted stock units, indicating future potential stock issuances.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. Investors often monitor these filings to gauge executive sentiment and potential future stock movements.
Comparison to Industry Standards
- Stock option grants and RSU vesting schedules are common compensation practices in the biotechnology industry, used to align executive incentives with long-term shareholder value.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation plans for their executives.
- The vesting schedules and exercise prices are generally in line with industry standards for executive compensation.
Stakeholder Impact
- Shareholders may monitor these transactions to understand executive sentiment and potential stock price impacts.
- Employees may be interested in the equity compensation trends for senior management.
Key Dates
| Date | Description |
|---|---|
| March 15, 2023 | Date the Reporting Person adopted a Rule 10b5-1 trading plan. |
| February 13, 2023 | Date the Reporting Person was granted an RSU that vested as to 2,083 shares on February 13, 2024, vested as to 2,083 shares on February 13, 2025, and will vest as to 2,083 shares on February 13, 2026, and 2,083 shares on February 13, 2027. |
| June 14, 2024 | Date the Reporting Person adopted a Rule 10b5-1 trading plan. |
| February 13, 2024 | Date the Reporting Person was granted an RSU that vested as to 1,961 shares on February 13, 2025, and will vest as to 1,961 shares on February 13, 2026, 1,962 shares on February 13, 2027, and 1,962 shares on February 13, 2028. |
| February 12, 2025 | Date of earliest transaction and grant date of stock options and restricted stock units. |
| February 13, 2025 | Date of stock transactions (acquisitions and disposals) and vesting of RSUs. |
| February 14, 2025 | Date of Form 4 filing. |
| March 12, 2025 | Date when 1/48th of the shares underlying the option becomes vested and exercisable. |
| February 12, 2026 | Date when 1/4 of the restricted stock units will vest. |
| February 12, 2027 | Date when 1/4 of the restricted stock units will vest. |
| February 12, 2028 | Date when 1/4 of the restricted stock units will vest. |
| February 12, 2029 | Date when 1/4 of the restricted stock units will vest. |
| 02/12/2035 | Expiration date of the stock options. |
Keywords
Neurocrine Biosciences, Eric Benevich, Form 4, insider trading, stock options, restricted stock units, 10b5-1 plan, NBIX, Chief Commercial Officer, stock sale, stock acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.